Medline Inc. Class A common stock (MDLN) Stock Price
MDLNStock
$35.96
Market Cap$48.38B
P/E40.79x
PEG Ratio—
Div yield—
Beta0.95
MDLN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.47%
Price vs S&P 500 (4W)13.84%
VGM Score41.23
P/E Ratio (Annual)40.79x
MDLN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.32 | $0.50 | +55.76%(+$0.18) | |
| Q1 2026 | $0.29 | $0.33 | +12.18%(+$0.04) | |
| Q4 2025 | $0.24 | $0.31 | +30.04%(+$0.07) |
MDLN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.15
4.15
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
| PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
About Medline Inc. Class A common stock
Medline is the largest medical-surgical products and supply chain solutions provider in the United States, generating over 90% of its revenue domestically. The company serves major US health systems as a prime vendor, offering approximately 190,000 proprietary products and 150,000 third-party sourced products through an integrated supply chain. Backed by 30+ manufacturing facilities and over 2,000 owned delivery trucks, Medline leverages significant operational scale and logistics advantages. The company completed its IPO in December 2025.